{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:43:44Z","timestamp":1780469024564,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.tem.2025.03.015","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:19:27Z","timestamp":1745497167000},"page":"504-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Promising results but caution needed in GLP-1RA large scale epidemiology"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Salil V.","family":"Deo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-1461","authenticated-orcid":false,"given":"Naveed A.","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2025.03.015_bb0005","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2025.03.015_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1364503","article-title":"Therapeutic advances in obesity management: an overview of the therapeutic interventions","volume":"15","author":"Roomy","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tem.2025.03.015_bb0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S2213-8587(22)00317-5","article-title":"Treating chronic diseases without tackling excess adiposity promotes multimorbidity","volume":"11","author":"Sattar","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2025.03.015_bb0020","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.03.015_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2025.03.015_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20105","article-title":"National and state estimates of SELECT trial eligibility and its public health impact in the US","volume":"7","author":"Erhabor","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tem.2025.03.015_bb0035","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2025.03.015_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-8587(24)00363-2","article-title":"Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2025.03.015_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tem.2025.03.015_bb0050","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.03.015_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086454","article-title":"Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)","volume":"15","author":"Klausen","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.tem.2025.03.015_bb0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The magic of randomization versus the myth of real-world evidence","volume":"382","author":"Collins","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.03.015_bb0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(18)32840-X","article-title":"Real-world studies no substitute for RCTs in establishing efficacy","volume":"393","author":"Gerstein","year":"2019","journal-title":"Lancet"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327602500075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327602500075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:43:12Z","timestamp":1748875392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104327602500075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S104327602500075X"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2025.03.015","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promising results but caution needed in GLP-1RA large scale epidemiology","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2025.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}